Risk of Cancer-Specific Death May Remain Elevated for 30 Years
Patients with certain cancers have an increased risk of cancer-specific mortality that persists for 30 to 35 years after diagnosis.
Patients with certain cancers have an increased risk of cancer-specific mortality that persists for 30 to 35 years after diagnosis.
In all studied scenarios, PSA screening appeared more favorable for Black men than for the general population.
Although most men with low-risk prostate cancer are now managed initially with active surveillance, use of this approach remains suboptimal, according to investigators.
New findings challenge recommendations from the European Association of Urology.
The presence of perineural invasion in a prostate biopsy has important implications for active surveillance.
Active surveillance appears to be a safe treatment option for low- and very low-risk prostate cancer, regardless of race, according to investigators.
Some patients with a negative mpMRI while on prostate cancer active surveillance may be able to defer biopsy, according to investigators.
Study reveals factors that could distinguish PSA bounce from biochemical recurrence after stereotactic body radiation therapy for prostate cancer.
Grade group 1 prostate cancers declined as a proportion of all prostate cancers.
Following the approval of cabazitaxel in 2010, there are now an unprecedented number of life-prolonging therapies for men with metastatic disease.